uniQure Announces Initial Topline Data from Dose-Confirmation Study of AMT-061 in Patients with Hemophilia B
15 nov. 2018 07h00 HE
|
uniQure Inc.
~ All Patients Achieved and Sustained Therapeutic Factor IX Activity with a Mean FIX Level of 31% of Normal at Six Weeks After Administration ~ ~ None of the Patients Received Factor Infusions,...
uniQure Provides Update on Dose-Confirmation Study of AMT-061 in Patients with Hemophilia B
24 sept. 2018 07h00 HE
|
uniQure Inc.
~ Third patient treated in Phase IIb study ~ ~ Topline data expected to be available before the end of 2018 ~ LEXINGTON, Mass and AMSTERDAM, the Netherlands, Sept. 24, 2018 (GLOBE NEWSWIRE) --...